Show simple item record

dc.contributor.authorAtyeo, Caroline
dc.contributor.authorFischinger, Stephanie
dc.contributor.authorZohar, Tomer
dc.contributor.authorSlein, Matthew D.
dc.contributor.authorBurke, John
dc.contributor.authorLoos, Carolin
dc.contributor.authorMcCulloch, Denise J.
dc.contributor.authorNewman, Kira L.
dc.contributor.authorWolf, Caitlin
dc.contributor.authorYu, Jingyou
dc.contributor.authorShuey, Kiel
dc.contributor.authorFeldman, Jared
dc.contributor.authorHauser, Blake Marie
dc.contributor.authorCaradonna, Tim
dc.contributor.authorSchmidt, Aaron G.
dc.contributor.authorSuscovich, Todd J.
dc.contributor.authorLinde, Caitlyn
dc.contributor.authorCai, Yongfei
dc.contributor.authorBarouch, Dan
dc.contributor.authorRyan, Edward T.
dc.contributor.authorCharles, Richelle C.
dc.contributor.authorLauffenburger, Douglas A
dc.contributor.authorChu, Helen
dc.contributor.authorAlter, Galit
dc.date.accessioned2021-01-05T15:38:11Z
dc.date.available2021-01-05T15:38:11Z
dc.date.issued2020-09
dc.identifier.issn1074-7613
dc.identifier.urihttps://hdl.handle.net/1721.1/128955
dc.description.abstractAs SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development.en_US
dc.language.isoen
dc.publisherElsevier BVen_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.immuni.2020.07.020en_US
dc.rightsCreative Commons Attribution 4.0 International licenseen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceElsevieren_US
dc.titleDistinct Early Serological Signatures Track with SARS-CoV-2 Survivalen_US
dc.typeArticleen_US
dc.identifier.citationAtyeo, Caroline et al. "Distinct Early Serological Signatures Track with SARS-CoV-2 Survival." Immunity 53, 3 (September 2020): P524-532.e4 © 2020 The Authorsen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.relation.journalImmunityen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2021-01-04T17:31:25Z
dspace.orderedauthorsAtyeo, C; Fischinger, S; Zohar, T; Slein, MD; Burke, J; Loos, C; McCulloch, DJ; Newman, KL; Wolf, C; Yu, J; Shuey, K; Feldman, J; Hauser, BM; Caradonna, T; Schmidt, AG; Suscovich, TJ; Linde, C; Cai, Y; Barouch, D; Ryan, ET; Charles, RC; Lauffenburger, D; Chu, H; Alter, Gen_US
dspace.date.submission2021-01-04T17:31:48Z
mit.journal.volume53en_US
mit.journal.issue3en_US
mit.licensePUBLISHER_CC
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record